Dexcom shares sank more than 40% on Friday, their steepest decline ever, after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. Stream ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it ...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
Shares of Dexcom tumbled almost 40% in extended trading Thursday after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. Stream Los ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results